NATIONAL-TSING
On May 9 National Tsing Hua University entered into an agreement to jointly establish the Taipei School of Economics and Political Science (TSE) together with the TSE Foundation, which was set up with a US$100 million donation from entrepreneur Lin Chen-hai, the founder of the Pau Jar Group. The mission of the TSE will be to provide world-class education in economics, international politics, and public affairs, with Asia as the center of gravity, and will soon begin recruiting top-notch faculty from around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200512005343/en/
At the signing ceremony, TSE Foundation chairman Huang Huang-hsiung said that the TSE will be located on the NTHU campus, and that this type of cooperation between the public and private sectors is a new first in the history of higher education in Taiwan.
Also present at the ceremony was Minister of Education Pan Wen-chung, who said that the establishment of the TSE is undoubtedly a new milestone for higher education in Taiwan. NTHU president Hocheng Hong said that the plan for establishing the TSE has already been approved by the Ministry of Education, and that it will soon begin recruiting master’s and doctoral students for the 2021-22 school year, two thirds of whom will be international students, adding that all courses will be taught in English.
Chairman Huang said that the TSE aims to attract outstanding students and world-class faculty, for which purpose he is helping to set up an international advisory committee, which includes four former ministers of education to arrange academic exchanges with such well-known institutions as the London School of Economics(LSE) and the Harvard Kennedy School.
NTHU president Hocheng Hong said that public-private cooperation in education on such a scale is unprecedented, pointing out that Lin’s US$100 million donation is the largest ever made in the field of social science education in Taiwan.
Hocheng asserted that technology is a major factor in all of the most pressing challenges facing humanity, such as food security, environmental preservation, energy, war, and even epidemics, and that any viable solution must take account of technological, political, and economic factors, adding that this was one of the principle motivations for establishing the TSE at National Tsing Hua University.
Hocheng said that the TSE will be the eleventh college at NTHU, and that its multi-disciplinary master’s and doctoral programs will be modeled on those of the LSE. The TSE plans to admit at least ten master’s students for the 2021-22 school year, and in the following school year at least 40 master’s students and ten doctoral students, after which enrollment numbers will gradually increase year by year. During the initial phase, TSE classes will be held in the Innovation Incubation Building on the NTHU campus, until the program’s own building is completed both on campus and in Taipei.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005343/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom